A Detailed Cutaneous Manifestations Evaluation in Patients with Polycystic Ovary Syndrome
Archives of Medical Laboratory Sciences,
Vol. 7 (2021),
13 March 2021
,
Page 1-6 (e10)
https://doi.org/10.22037/amls.v7.30828
Abstract
Background and Aim: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age. The hypothalamus-pituitary-ovary axis dysregulates in PCOS, ultimately leading to hyperandrogenisms. Consequently, it is associated with hirsutism, dyslipidemia, obesity, infertility, menstrual disturbance, and insulin resistance. To our knowledge, there is no detailed investigation of these manifestations. That is why, this study aimed to evaluate manifestations of hyperandrogenism, hirsutism in particular.
Methods: This study was performed on 39 women with an initial diagnosis of polycystic ovary syndrome. Rotterdam criteria including Oligo- or anovulation, hyperandrogenism clinical and/or biochemical signs, and ultrasound appearance of polycystic ovaries used as diagnostic criteria. Hirsutism scoring was carried out according to Freeman-Gallwey’s definition of hirsutism. The patients were analyzed for other skin problems including male pattern baldness, acanthosis nigricans, and acne as well as demographic features.
Results: Hirsutism was observed in the majority of our patients (91%) ranging from mild to severe. Concerning the distribution of hirsutism on various parts of the body, severe hirsutism was observed more on the groin, abdominal area, and chin respectively. Male pattern baldness, acanthosis nigricans, and acne, and dysregulated menstruation were reported in these patients.
Conclusion: This investigation found that skin manifestations, especially hirsutism, are highly frequent in patients with PCOS.
*Corresponding Author: Hashem Nayeri; Email: hnaieri@gmail.com; nayeri@iaufala.ac.ir
Please cite this article as: Masaeli A, Nayeri H, Mirzaei M. A Detailed Cutaneous Manifestations Evaluation in Patients with Polycystic Ovary Syndrome. Arch Med Lab Sci. 2021;7:1-6 (e10). https://doi.org/10.22037/amls.v7.30828
- Polycystic Ovary Syndrome
- Hyperandrogenism
- Testosterone
- Androgen
- Hirsutism
How to Cite
References
Chang RJ, Dumesic DA. Polycystic ovary syndrome and hyperandrogenic states. InYen and Jaffe's reproductive endocrinology 2019 Jan 1 (pp. 520-555).
Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nature Reviews Endocrinology. 2018 May;14(5):270.
Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nature reviews Disease primers. 2016 Aug 11;2(1):1-8.
McCartney CR, Marshall JC. Polycystic ovary syndrome. New England Journal of Medicine. 2016 Jul 7;375(1):54-64.
Houjeghani S, Gargari BP, Farzadi L. Serum leptin and ghrelin levels in women with polycystic ovary syndrome: correlation with anthropometric, metabolic, and endocrine parameters. International journal of fertility & sterility. 2012 Jul;6(2):117.
Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine reviews. 2015 Oct 1;36(5):487-525.
Wild RA, Rizzo M, Clifton S, Carmina E. Lipid levels in polycystic ovary syndrome: systematic review and meta-analysis. Fertility and sterility. 2011 Mar 1;95(3):1073-9.
Dumitrescu R, Mehedintu C, Briceag I, Purcarea VL, Hudita D. The polycystic ovary syndrome: an update on metabolic and hormonal mechanisms. Journal of medicine and life. 2015 Apr;8(2):142.
Yildiz BO, Bolour S, Woods K, Moore A, Azziz R. Visually scoring hirsutism. Human reproduction update. 2010 Jan 1;16(1):51-64.
Ehrman DA, Barnes RB, Rosenfield RL. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion. Endocrine reviews. 1995 Jun 1;16(3):322-53.
Eagleson CA, Gingrich MB, Pastor CL, Arora TK, Burt CM, Evans WS, Marshall JC. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. The Journal of Clinical Endocrinology & Metabolism. 2000 Nov 1;85(11):4047-52.
Pastor CL, Griffin-Korf ML, Aloi JA, Evans WS, Marshall JC. Polycystic ovary syndrome: evidence for reduced sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. The Journal of Clinical Endocrinology & Metabolism. 1998 Feb 1;83(2):582-90.
Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocrine reviews. 2012 Dec 1;33(6):981-1030.
ESHRE TR, ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertility and sterility. 2004 Jan 1;81(1):19-25.
Ashraf S, Nabi M, Rashid F, Amin S. Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review. Egyptian Journal of Medical Human Genetics. 2019 Dec 1;20(1):25.
Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertility and sterility. 2002 Jun 1;77(6):1095-105.
Panidis D, Tziomalos K, Papadakis E, Chatzis P, Kandaraki EA, Tsourdi EA, Macut D, Bjekic-Macut J, Marthopoulos A, Katsikis I. Associations of menstrual cycle irregularities with age, obesity and phenotype in patients with polycystic ovary syndrome. Hormones. 2015 Jul 1;14(3):431-7.
Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertility and sterility. 2009 Feb 1;91(2):456-88..
Carmina E. Cutaneous manifestations of Polycystic ovary syndrome. Current Opinion in Endocrine and Metabolic Research. 2020 Mar 9.
Legro RS, Arslanian SA, Ehrmann DA, Hoeger KM, Murad MH, Pasquali R, Welt CK. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. The Journal of Clinical Endocrinology & Metabolism. 2013 Dec 1;98(12):4565-92.
Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, Piltonen T, Norman RJ. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human reproduction. 2018 Sep 1;33(9):1602-18.
Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, Taylor K, Boots LR. Androgen excess in women: experience with over 1000 consecutive patients. The Journal of Clinical Endocrinology & Metabolism. 2004 Feb 1;89(2):453-62.
Escobar-Morreale HF, Carmina E, Dewailly D, Gambineri A, Kelestimur F, Moghetti P, Pugeat M, Qiao J, Wijeyaratne CN, Witchel SF, Norman RJ. Epidemiology, diagnosis and management of hirsutism: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome Society. Human reproduction update. 2012 Mar 1;18(2):146-70.
Carmina E, Rosato F, Janni A, Rizzo M, Longo RA. Relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. The Journal of Clinical Endocrinology & Metabolism. 2006 Jan 1;91(1):2-6.
Gupta S., Pandithurai E., Agarwal A. (2016) Polycystic Ovary Syndrome in Adolescent Girls. In: Kumanov P., Agarwal A. (eds) Puberty. Springer, Cham. https://doi.org/10.1007/978-3-319-32122-6_16
- Abstract Viewed: 127 times
- PDF Downloaded: 87 times